Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore (Nasdaq: IMCR) announced management will present at multiple investor conferences in March 2026, including TD Cowen (Mar 3), Leerink (Mar 9), Barclays (Mar 10), UBS Biotech Summit (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
Where relevant, presentations will be webcast live via the company’s Investors > Events & Presentations page, with replays available for a limited time.
Immunocore (Nasdaq: IMCR) reported KIMMTRAK net sales of $104.5M in Q4 2025 and $400.0M for FY2025, cash and marketable securities of $864.2M, R&D spend of $274.9M, and a FY net loss of $35.5M.
The company expects TEBE-AM enrollment to complete in 1H 2026 with topline OS data as early as 2H 2026, PRAME and HIV data in 2H 2026, and an autoimmune Phase 1 start in 1H 2026.
Immunocore (Nasdaq: IMCR) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss results and provide a business and portfolio update.
Investors can access the live audio webcast via the 'Events' page in the Investors section at www.immunocore.com; a replay will be available for a limited time.
Immunocore (Nasdaq: IMCR) announced an R&D leadership evolution: Dr. David Berman will depart effective 27 February 2026 and the company will not hire a direct replacement.
The company is promoting Dr. Mohammed Dar to EVP, clinical development and Mark Moyer to EVP, Chief Regulatory and Quality Officer, consolidating clinical and regulatory oversight while citing three ongoing Phase 3 trials and KIMMTRAK approval in 39 countries.
Immunocore (Nasdaq: IMCR) outlined 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference, focused on expanding KIMMTRAK (tebentafusp) access, advancing three registrational Phase 3 melanoma trials (including TEBE-AM enrollment completion expected 1H 2026 with topline as early as 2H 2026) and multiple Phase 1/2 readouts in 2026 for PRAME bispecifics.
The company plans first autoimmune dosing in 1H 2026, HIV data in 2H 2026, and reported preliminary year-end 2025 cash of approximately $864 million.
Immunocore (Nasdaq: IMCR) announced management will present at two investor conferences in November 2025: a Guggenheim 2nd Annual Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 3:00 p.m. EST, and a Jefferies London Healthcare Conference fireside chat on Wednesday, November 19, 2025 at 3:30 p.m. GMT.
Where relevant, presentations will be webcast live and available under Investors > Events & Presentations on Immunocore's website, with replays posted for a limited time.
Immunocore (Nasdaq: IMCR) presented Phase 1 single‑ascending‑dose data for IMC-I109V at AASLD The Liver Meeting on November 7, 2025. The bispecific TCR candidate showed a manageable safety profile and pharmacodynamic activity consistent with its mechanism, including dose‑dependent reductions in HBsAg at doses ≥ 7 mcg, with HBsAg nadirs typically by day 8. Four participants met the predefined ≥ 0.2 log10 HBsAg reduction threshold. Treatment‑related adverse events were mostly transient; one Grade 2 cytokine release syndrome at 20 mcg resolved with treatment.
The company plans further evaluation in multiple‑dose regimens.
Immunocore (Nasdaq: IMCR) reported 3Q 2025 results and a business update on November 6, 2025. KIMMTRAK net product sales were $103.7M in the quarter (+29% YoY) and $295.5M year-to-date. Cash, cash equivalents and marketable securities were $892.4M as of September 30, 2025. The company is advancing multiple registrational trials: Phase 3 TEBE-AM (enrollment on track to complete 1H 2026) and Phase 3 PRISM-MEL-301 (brenetafusp 160 mcg selected by IDMC). R&D and SG&A increased QoQ, and GAAP net loss was ($0.2M) in 3Q 2025. Key pipeline areas include oncology (PRAME, IMC-R117C), infectious disease (HIV, HBV), and autoimmune programs.
Resolution Therapeutics has strengthened its leadership team with two key appointments: Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The appointments follow the successful dosing of the first patient in the company's Phase I/II EMERALD study.
Lucy Singah brings over 20 years of corporate and strategic finance experience from companies including Echopoint Medical, GSK, and EY. Daniel Kennedy, with more than 20 years of business development experience, joins from Immunocore (NASDAQ: IMCR) and previously led deals at Achillion Pharmaceuticals, including its $930 million acquisition by Alexion.
The company will host an R&D Webinar on September 17, 2025, featuring clinical hepatologists to discuss its regenerative macrophage therapy (RMT) platform for inflammatory and fibrotic diseases.
Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company will participate in the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Morgan Stanley Global Healthcare Conference (Sept 10).
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their flagship product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.